For decades, registering a medicine in Africa has meant opening a separate file in every market: a different dossier format, a different fee schedule, a different review clock. The African Medicines Agency (AMA), established under the African Union treaty and headquartered in Kigali, is designed to change that arithmetic, not by replacing national regulators, but by coordinating them.
What actually changes
AMA does not turn 55 markets into one overnight. Its value is in coordination: shared scientific assessment, reliance on the work of trusted regulators, and gradually converging technical requirements. Companies that already file through regional routes will recognise the direction of travel from the EAC joint assessment procedure and the ZaZiBoNa collaboration in southern Africa.
Where the transition is still open
The operating model is still being built out. Which products are routed through continental assessment, how national authorities recognise outcomes, and how timelines compare with existing national routes are all questions that will settle as the agency matures. Treat any single timeline you hear as provisional and confirm current requirements with each authority before committing a launch date.
What we advise sponsors to do now
- Map your portfolio against the regional procedures already available (EAC, ZaZiBoNa, WHO collaborative registration) and note where each product could be routed.
- Build a single core dossier of record, with a gap analysis against each target authority, so that adapting it is a controlled exercise rather than a rewrite.
- Review pharmacovigilance and lifecycle commitments early. Reliance accelerates approval; it does not reduce post-market obligations.
- Keep a living regulatory-intelligence file for each market so that policy change feeds into launch sequencing, not into surprises.
The winners will not be the companies that file first everywhere. They will be the ones whose dossiers travel well.
If you would like a view of how AMA and the regional procedures affect a specific product or portfolio, our regulatory-intelligence team can prepare a market-by-market pathway map.
